Barclays lowered the firm’s price target on Novo Nordisk to DKK 725 from DKK 1,450 and keeps an Overweight rating on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Novo Nordisk conducts two-for-one stock split
- Novo Nordisk call volume above normal and directionally bullish
- Novo Nordisk reaches pact with New York AG over insulin prices
- Novo Nordisk price target raised to DKK 1,500 from DKK 1,200 at JPMorgan
- SomaLogic expands agreement with Novo Nordisk to 2025
Questions or Comments about the article? Write to editor@tipranks.com